Background/Aims: Arachidonic acid-metabolizing enzyme, 12-lipoxygenase (12-LO), is involved in the glomerular hypertrophy of diabetic nephropathy (DN), in which cyclin-dependent kinase inhibitors (CKIs) play important roles. However, it is unclear whether 12-LO regulates the expression of the CKI p16ink4a in DN. Methods: Primary glomerular mesangial cells (MCs) and glomeruli isolated from rats were used in this study. The rats were fed a high-fat diet and given low-dose streptozotocin to induce type 2 diabetes. The 12-LO product, 12(S)-hydroxyeicosatetraenoic acid (12(S)-HETE), was infused through an osmotic minipump. Enzyme-linked immunosorbent assay, Western blot, and morphometric analyses were performed. Results: High glucose (HG) increased the p16ink4a protein expression in MCs, but this increase was prevented by the 12-LO inhibitor, cinnamyl-3,​4-dihydroxy-α-cynanocinnamate (CDC). The levels of p-p38MAPK and p16ink4a in MCs were significantly elevated after the 12(S)-HETE treatment, whereas the p38MAPK inhibitor SB203580 prevented these increases. Compared with levels in control MCs, marked increases in p38MAPK activation and p16ink4a expression were observed in MCs plated on collagen IV, while the CDC treatment prevented these changes. Subcutaneous injection of CDC did not affect glucose levels, but completely attenuated the diabetes-related increases in the 12(S)-HETE content, p16ink4a expression, p-p38MAPK levels, glomerular volume, and the kidney/body weight ratio. Compared with levels in controls, p16ink4a and p-p38MAPK in the glomeruli derived from 12(S)-HETE-treated rats were significantly higher. Conclusions: 12-LO-p38MAPK mediates the upregulation of p16ink4a in HG-stimulated MCs and type 2-diabetic glomeruli, and new therapies aimed at 12-LO inhibition may prove beneficial in ameliorating diabetes-induced glomerular hypertrophy.

Keywords:
p16ink4a, 12-lipoxygenase, 12(S)-hydroxyeicosatetraenoic acid, Diabetic nephropathy
1.
Wolf G, Ziyadeh FN: Molecular mechanisms of diabetic renal hypertrophy. Kidney Int 1999;56:393-405.
2.
Young BA, Johnson RJ, Alpers CE, Eng E, Gordon K, Floege J, Couser WG, Seidel K: Cellular events in the evolution of experimental diabetic nephropathy. Kidney Int 1995;47:935-944.
3.
Wolf G, Sharma K, Chen Y, Ericksen M, Ziyadeh FN: High glucose-induced proliferation in mesangial cells is reversed by autocrine TGF-beta. Kidney Int 1992;42:647-656.
4.
Nahman NS Jr, Leonhart KL, Cosio FG, Hebert CL: Effects of high glucose on cellular proliferation and fibronectin production by cultured human mesangial cells. Kidney Int 1992;41:396-402.
5.
Sherr CJ, Roberts JM: Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev 1995;9:1149-1163.
6.
Kuan CJ, al-Douahji M, Shankland SJ: The cyclin kinase inhibitor p21WAF1, CIP1 is increased in experimental diabetic nephropathy: potential role in glomerular hypertrophy. J Am Soc Nephrol 1998;9:986-993.
7.
Wolf G, Schroeder R, Thaiss F, Ziyadeh FN, Helmchen U, Stahl RA: Glomerular expression of p27Kip1 in diabetic db/db mouse: role of hyperglycemia. Kidney Int 1998;53:869-879.
8.
del Nogal M, Troyano N, Calleros L, Griera M, Rodriguez-Puyol M, Rodriguez-Puyol D, Ruiz-Torres MP: Hyperosmolarity induced by high glucose promotes senescence in human glomerular mesangial cells. Int J Biochem Cell Biol 2014;54:98-110.
9.
Verzola D, Gandolfo MT, Gaetani G, Ferraris A, Mangerini R, Ferrario F, Villaggio B, Gianiorio F, Tosetti F, Weiss U, Traverso P, Mji M, Deferrari G, Garibotto G: Accelerated senescence in the kidneys of patients with type 2 diabetic nephropathy. Am J Physiol Renal Physiol 2008;295:F1563-F1573.
10.
Wolf G, Wenzel U, Ziyadeh FN, Stahl RA: Angiotensin converting-enzyme inhibitor treatment reduces glomerular p16INK4 and p27Kip1 expression in diabetic BBdp rats. Diabetologia 1999;42:1425-1432.
11.
Satriano J, Mansoury H, Deng A, Sharma K, Vallon V, Blantz RC, Thomson SC: Transition of kidney tubule cells to a senescent phenotype in early experimental diabetes. Am J Physiol Cell Physiol 2010;299:C374-C380.
12.
Yamamoto S: Mammalian lipoxygenases: molecular structures and functions. Biochim Biophys Acta 1992;1128:117-131.
13.
Funk CD: The molecular biology of mammalian lipoxygenases and the quest for eicosanoid functions using lipoxygenase-deficient mice. Biochim Biophys Acta 1996;1304:65-84.
14.
Kang SW, Adler SG, Nast CC, LaPage J, Gu JL, Nadler JL, Natarajan R: 12-lipoxygenase is increased in glucose-stimulated mesangial cells and in experimental diabetic nephropathy. Kidney Int 2001;59:1354-1362.
15.
Natarajan R, Bai W, Rangarajan V, Gonzales N, Gu JL, Lanting L, Nadler JL: Platelet-derived growth factor BB mediated regulation of 12-lipoxygenase in porcine aortic smooth muscle cells. J Cell Physiol 1996;169:391-400.
16.
Natarajan R, Gonzales N, Lanting L, Nadler J: Role of the lipoxygenase pathway in angiotensin II-induced vascular smooth muscle cell hypertrophy. Hypertension 1994;23(1 suppl):I142-I147.
17.
Reddy MA, Adler SG, Kim YS, Lanting L, Rossi J, Kang SW, Nadler JL, Shahed A, Natarajan R: Interaction of MAPK and 12-lipoxygenase pathways in growth and matrix protein expression in mesangial cells. Am J Physiol Renal Physiol 2002;283:F985-F994.
18.
Reddy MA, Thimmalapura PR, Lanting L, Nadler JL, Fatima S, Natarajan R: The oxidized lipid and lipoxygenase product 12(S)-hydroxyeicosatetraenoic acid induces hypertrophy and fibronectin transcription in vascular smooth muscle cells via p38 MAPK and cAMP response element-binding protein activation. Mediation of angiotensin II effects. J Biol Chem 2002;277:9920-9928.
19.
Pozzi A, Zent R, Chetyrkin S, Borza C, Bulus N, Chuang P, Chen D, Hudson B, Voziyan P: Modification of collagen IV by glucose or methylglyoxal alters distinct mesangial cell functions. J Am Soc Nephrol 2009;20:2119-2125.
20.
Anderson SS, Kim Y, Tsilibary EC: Effects of matrix glycation on mesangial cell adhesion, spreading and proliferation. Kidney Int 1994;46:1359-1367.
21.
Xu ZG, Miao LN, Cui YC, Jia Y, Yuan H, Wu M: Angiotensin II type 1 receptor expression is increased via 12-lipoxygenase in high glucose-stimulated glomerular cells and type 2 diabetic glomeruli. Nephrol Dial Transplant 2009;24:1744-1752.
22.
Ishizawa K, Dorjsuren N, Izawa-Ishizawa Y, Sugimoto R, Ikeda Y, Kihira Y, Kawazoe K, Tomita S, Tsuchiya K, Minakuchi K, Tamaki T: Inhibitory effects of adiponectin on platelet-derived growth factor-induced mesangial cell migration. J Endocrinol 2009;202:309-316.
23.
Nakajima T, Hasegawa G, Kamiuchi K, Fukui M, Yamasaki M, Tominaga M, Asano M, Hosoda H, Yoshikawa T, Nakamura N: Differential regulation of intracellular redox state by extracellular matrix proteins in glomerular mesangial cells: potential role in diabetic nephropathy. Redox Rep 2006;11:223-230.
24.
Weibel ER: Practical methods for biological morphometry; in Stereological Methods, London, Academic Press, 1979, pp 44-45.
25.
Ivanchuk SM, Mondal S, Dirks PB, Rutka JT: The INK4A/ARF locus: role in cell cycle control and apoptosis and implications for glioma growth. J Neurooncol 2001;51:219-229.
26.
Nobrega MA, Fleming S, Roman RJ, Shiozawa M, Schlick N, Lazar J, Jacob HJ: Initial characterization of a rat model of diabetic nephropathy. Diabetes 2004;53:735-742.
27.
Janssen U, Phillips AO, Floege J: Rodent models of nephropathy associated with type II diabetes. J Nephrol 1999;12:159-172.
28.
Vora JP, Zimsen SM, Houghton DC, Anderson S: Evolution of metabolic and renal changes in the ZDF/Drt-fa rat model of type II diabetes. J Am Soc Nephrol 1996;7:113-117.
29.
Danda RS, Habiba NM, Rincon-Choles H, Bhandari BK, Barnes JL, Abboud HE, Pergola PE: Kidney involvement in a nongenetic rat model of type 2 diabetes. Kidney Int 2005;68:2562-2571.
30.
Hoffman BB, Sharma K, Ziyadeh FN: Potential role of TGF-beta in diabetic nephropathy. Miner Electrolyte Metab 1998;24:190-196.
31.
Huang HC, Preisig PA: G1 kinases and transforming growth factor-beta signaling are associated with a growth pattern switch in diabetes-induced renal growth. Kidney Int 2000;58:162-172.
32.
Kim YS, Xu ZG, Reddy MA, Li SL, Lanting L, Sharma K, Adler SG, Natarajan R: Novel interactions between TGF-{beta}1 actions and the 12/15-lipoxygenase pathway in mesangial cells. J Am Soc Nephrol 2005;16:352-362.
33.
Wang W, Pan K, Chen Y, Huang C, Zhang X: The acetylation of transcription factor HBP1 by p300/CBP enhances p16INK4A expression. Nucleic Acids Res 2012;40:981-995.
34.
Krishnamurthy J, Torrice C, Ramsey MR, Kovalev GI, Al-Regaiey K, Su L, Sharpless NE: Ink4a/Arf expression is a biomarker of aging. J Clin Invest 2004;114:1299-1307.
35.
Melk A, Schmidt BM, Vongwiwatana A, Rayner DC, Halloran PF: Increased expression of senescence-associated cell cycle inhibitor p16INK4a in deteriorating renal transplants and diseased native kidney. Am J Transplant 2005;5:1375-1382.
36.
Melk A, Schmidt BM, Takeuchi O, Sawitzki B, Rayner DC, Halloran PF: Expression of p16INK4a and other cell cycle regulator and senescence associated genes in aging human kidney. Kidney Int 2004;65:510-520.
37.
Chkhotua AB, Gabusi E, Altimari A, D'Errico A, Yakubovich M, Vienken J, Stefoni S, Chieco P, Yussim A, Grigioni WF: Increased expression of p16(INK4a) and p27(Kip1) cyclin-dependent kinase inhibitor genes in aging human kidney and chronic allograft nephropathy. Am J Kidney Dis 2003;41:1303-1313.
38.
Mason RM, Wahab NA: Extracellular matrix metabolism in diabetic nephropathy. J Am Soc Nephrol 2003;14:1358-1373.
39.
Kang SW, Natarajan R, Shahed A, Nast CC, LaPage J, Mundel P, Kashtan C, Adler SG: Role of 12-lipoxygenase in the stimulation of p38 mitogen-activated protein kinase and collagen alpha5(IV) in experimental diabetic nephropathy and in glucose-stimulated podocytes. J Am Soc Nephrol 2003;14:3178-3187.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.